Cerus Revenue Growth Rates (CERS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cerus Corporation  (NASDAQ: CERS)
 

CERS's Revenue Growth by Quarter and Year

Cerus's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CERS/growth
https://api.csimarket.com/api/v1/companies/CERS/fundamentals
https://api.csimarket.com/api/v1/companies/CERS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CERS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 57.71
2nd Quarter June 57.44
1st Quarter March 52.89
FY 168.04

CERSs Annual Revenue
Cerus's Revenue in the fiscal year 2025 $ 205.29 millions
Cerus's Revenue in the fiscal year 2024 $ 179.52 millions
Cerus's Revenue in the fiscal year 2023 $ 155.40 millions
Cerus's Revenue in the fiscal year 2022 $ 162.05 millions
Cerus's Revenue in the fiscal year 2021 $ 130.86 millions




CERS Revenue third quarter 2026 Y/Y Growth Comment
Cerus Corporation reported Revenue increase of 10.69% year on year in the third quarter 2026, to $ 57.71 millions, this is lower than Cerus Corporation's recent average Revenue improvement of 25.91%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 92 other companies have achieved higher Revenue growth. While Cerus Corporation' s Revenue growth of 10.69% ranks overall at the positon no. 1685 in the third quarter 2026.


CERS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.69 %
2nd Quarter June 10.5 %
1st Quarter March 24.68 %
FY   -

Financial Statements
Cerus's third quarter 2026 Revenue $ 57.71 millions CERS's Income Statement
Cerus's third quarter 2025 Revenue $ 52.14 millions Quarterly CERS's Income Statement


CERS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.48 %
2nd Quarter June 8.6 %
1st Quarter March -9.97 %
FY (Year on Year)   -


Back to CERS Growth rate Comparisons >> Back to CERS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #93
Healthcare Sector #271
Overall #1685

Revenue Y/Y Growth Statistics
High Average Low
344.79 % 25.91 % -55.65 %
(Sep 30 2018)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #93
Healthcare Sector #271
Overall #1685
Revenue Y/Y Growth Statistics
High Average Low
344.79 % 25.91 % -55.65 %
(Sep 30 2018)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cerus's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
317.11 % 10.59 % -70.94 %
(Dec 31 2017)  


CERS's III. Quarter Q/Q Revenue Comment
Cerus Corporation achieved in the III. Quarter 2026 below company average Revenue growth of 0.48% quarter on quarter, to $ 57.71 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 0.31% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Cerus's Revenue growth quarter on quarter, overall rank is 897.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #37
Healthcare Sector #137
Overall #897
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #37
Healthcare Sector #137
Overall #897
Revenue Q/Q Growth Statistics
High Average Low
317.11 % 10.59 % -70.94 %
(Dec 31 2017)  


CERS's III. Quarter Q/Q Revenue Comment
Cerus Corporation achieved in the III. Quarter 2026 below company average Revenue growth of 0.48% quarter on quarter, to $ 57.71 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 0.31% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Cerus's Revenue growth quarter on quarter, overall rank is 897.


Cerus's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 226.80
Y / Y Revenue Growth (TTM) 14.59 %
Year on Year Revenue Growth Overall Ranking # 1245
Seqeuential Revenue Change (TTM) 2.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 2197


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Cerus's cumulative twelve months Revenue were $ 227 millions, company would post below average annual Revenue growth of 2.52% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Cerus's Revenue growth from the 57.44% growth in Jun 30 2026.

In the Healthcare sector 220 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 710 to 1245.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 119
Healthcare Sector # 221
Overall # 1245

Revenue TTM Y/Y Growth Statistics
High Average Low
181.26 %
 20.24 %
-45.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 324
S&P 500 # 2197
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Cerus's cumulative twelve months Revenue were $ 227 millions, company would post below average annual Revenue growth of -45.88% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Cerus's Revenue growth from the 57.44% growth in Jun 30 2026.

In the Healthcare sector 220 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 710 to 1245.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 119
Healthcare Sector # 221
Overall # 1245

Revenue TTM Y/Y Growth Statistics
High Average Low
181.26 %
20.24 %
-45.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 324
S&P 500 # 2197




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CERS's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions


About Cerus Revenue Growth Rates (CERS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cerus Corp (CIK 1020214).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-443694
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cerus Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.